As Her­ceptin biosim­i­lars eat in­to Roche sales, Swiss drug­mak­er makes case for ex­pand­ed Kad­cy­la use

As the biosim­i­lar sharks bite in­to the sales of Roche’s decades-old block­buster Her­ceptin, the Swiss drug­mak­er is bet­ting on the broad­er use of Kad­cy­la, an an­ti­body drug con­ju­gate (ADC) that at­tach­es a chemother­a­peu­tic agent on to Her­ceptin to thwart can­cer cell growth.

Roche’s top-sell­ing can­cer treat­ment Her­ceptin saw a 16% drop in Eu­ro­pean sales last year af­ter the launch of biosim­i­lars in the mid­dle of 2018, and fresh biosim­i­lars are ex­pect­ed to hit the mar­ket in 2019. Mean­while Kad­cy­la gen­er­at­ed sales of 979 mil­lion Swiss francs ($981 mil­lion) in 2018, and is cur­rent­ly ap­proved for pa­tients with HER2-pos­i­tive breast can­cer that has pro­gressed de­spite treat­ment with Her­ceptin and chemother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.